The $400bn megadeal brewing in big pharma

AstraZeneca is in discussions with Bristol Myers Squibb that could result in a merger forming the world’s fourth-largest pharmaceutical company by market value. Such a deal would reshape the landscape of the pharmaceutical industry, potentially leading to more innovation and significant changes in drug pricing and availability. The implications extend beyond the companies involved, affecting global healthcare, as the combined entity could wield more influence in research, development, and distribution of medications. For investors and stakeholders, this merger signals a major shift in the industry’s competitive dynamics.